nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—FKBP1A—ALK1 signaling events—SMAD7—systemic scleroderma	0.0178	0.0697	CbGpPWpGaD
Pimecrolimus—MTOR—blood vessel—systemic scleroderma	0.0156	0.172	CbGeAlD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—SMAD7—systemic scleroderma	0.0151	0.0591	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.0119	0.0465	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling—SMAD7—systemic scleroderma	0.0102	0.0401	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—AIF1—systemic scleroderma	0.0101	0.0396	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—SMAD7—systemic scleroderma	0.00994	0.0389	CbGpPWpGaD
Pimecrolimus—FKBP1A—Alpha-synuclein signaling—BLK—systemic scleroderma	0.00949	0.0371	CbGpPWpGaD
Pimecrolimus—MTOR—EGFR-dependent Endothelin signaling events—EDN1—systemic scleroderma	0.00925	0.0362	CbGpPWpGaD
Pimecrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—SMAD7—systemic scleroderma	0.00807	0.0316	CbGpPWpGaD
Pimecrolimus—MTOR—connective tissue—systemic scleroderma	0.008	0.0882	CbGeAlD
Pimecrolimus—MTOR—smooth muscle tissue—systemic scleroderma	0.00732	0.0807	CbGeAlD
Pimecrolimus—MTOR—skin of body—systemic scleroderma	0.00722	0.0796	CbGeAlD
Pimecrolimus—FKBP1A—connective tissue—systemic scleroderma	0.0072	0.0793	CbGeAlD
Pimecrolimus—MTOR—IFN-gamma pathway—SMAD7—systemic scleroderma	0.0067	0.0262	CbGpPWpGaD
Pimecrolimus—FKBP1A—smooth muscle tissue—systemic scleroderma	0.00658	0.0726	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—systemic scleroderma	0.0065	0.0716	CbGeAlD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.00638	0.025	CbGpPWpGaD
Pimecrolimus—MTOR—digestive system—systemic scleroderma	0.00578	0.0637	CbGeAlD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling—CTGF—systemic scleroderma	0.00566	0.0221	CbGpPWpGaD
Pimecrolimus—MTOR—tendon—systemic scleroderma	0.0055	0.0606	CbGeAlD
Pimecrolimus—FKBP1A—digestive system—systemic scleroderma	0.0052	0.0573	CbGeAlD
Pimecrolimus—FKBP1A—tendon—systemic scleroderma	0.00495	0.0545	CbGeAlD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00494	0.0193	CbGpPWpGaD
Pimecrolimus—MTOR—lung—systemic scleroderma	0.00483	0.0532	CbGeAlD
Pimecrolimus—FKBP1A—Spinal Cord Injury—SELP—systemic scleroderma	0.0044	0.0172	CbGpPWpGaD
Pimecrolimus—FKBP1A—lung—systemic scleroderma	0.00434	0.0479	CbGeAlD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)—TGFB1—systemic scleroderma	0.00418	0.0164	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—SELP—systemic scleroderma	0.00415	0.0162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—RHOB—systemic scleroderma	0.00411	0.0161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00406	0.0159	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—COL1A2—systemic scleroderma	0.00365	0.0143	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00364	0.0142	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD247—systemic scleroderma	0.0034	0.0133	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CSK—systemic scleroderma	0.00327	0.0128	CbGpPWpGaD
Pimecrolimus—MTOR—Interferon type I signaling pathways—STAT4—systemic scleroderma	0.00326	0.0127	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD247—systemic scleroderma	0.00308	0.012	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.00304	0.0119	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—STAT4—systemic scleroderma	0.003	0.0117	CbGpPWpGaD
Pimecrolimus—FKBP1A—ALK1 signaling events—TGFB1—systemic scleroderma	0.00284	0.0111	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.00276	0.0108	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.0026	0.0102	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00245	0.0096	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.00241	0.00941	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—systemic scleroderma	0.0024	0.0094	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—CSK—systemic scleroderma	0.00237	0.00926	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CTLA4—systemic scleroderma	0.00233	0.00913	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.00228	0.0089	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFR2 mediated vascular permeability—NOS3—systemic scleroderma	0.00227	0.0089	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL1A—systemic scleroderma	0.00209	0.00817	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—CD40LG—systemic scleroderma	0.00195	0.00764	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—systemic scleroderma	0.00192	0.00751	CbGpPWpGaD
Pimecrolimus—CYP3A4—digestive system—systemic scleroderma	0.0017	0.0187	CbGeAlD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.00163	0.0064	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling—TGFB1—systemic scleroderma	0.00163	0.00637	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.0016	0.00626	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.00158	0.00618	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00155	0.00606	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—CSK—systemic scleroderma	0.00151	0.0059	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.0015	0.00585	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CCL2—systemic scleroderma	0.00144	0.00561	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.00142	0.00557	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—IL1B—systemic scleroderma	0.00137	0.00537	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.0013	0.00509	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.00129	0.00504	CbGpPWpGaD
Pimecrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—systemic scleroderma	0.00128	0.00503	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—BLK—systemic scleroderma	0.00123	0.0048	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL1B—systemic scleroderma	0.00109	0.00426	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL1B—systemic scleroderma	0.00105	0.00411	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—NOS3—systemic scleroderma	0.00103	0.00404	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—MMP9—systemic scleroderma	0.00103	0.00402	CbGpPWpGaD
Pimecrolimus—Eye disorder—Mycophenolic acid—systemic scleroderma	0.000999	0.00153	CcSEcCtD
Pimecrolimus—Paraesthesia—Mometasone—systemic scleroderma	0.000988	0.00151	CcSEcCtD
Pimecrolimus—Dyspnoea—Mometasone—systemic scleroderma	0.000981	0.0015	CcSEcCtD
Pimecrolimus—Malnutrition—Leflunomide—systemic scleroderma	0.000976	0.00149	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Captopril—systemic scleroderma	0.000966	0.00148	CcSEcCtD
Pimecrolimus—Rhinitis—Lisinopril—systemic scleroderma	0.000965	0.00148	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000964	0.00147	CcSEcCtD
Pimecrolimus—Pharyngitis—Lisinopril—systemic scleroderma	0.000956	0.00146	CcSEcCtD
Pimecrolimus—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.000945	0.00145	CcSEcCtD
Pimecrolimus—Back pain—Leflunomide—systemic scleroderma	0.000944	0.00144	CcSEcCtD
Pimecrolimus—Pain—Mometasone—systemic scleroderma	0.000941	0.00144	CcSEcCtD
Pimecrolimus—Infestation—Mycophenolate mofetil—systemic scleroderma	0.00094	0.00144	CcSEcCtD
Pimecrolimus—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.00094	0.00144	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000939	0.00144	CcSEcCtD
Pimecrolimus—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000931	0.00142	CcSEcCtD
Pimecrolimus—Conjunctivitis—Mycophenolate mofetil—systemic scleroderma	0.000914	0.0014	CcSEcCtD
Pimecrolimus—Skin exfoliation—Methotrexate—systemic scleroderma	0.000909	0.00139	CcSEcCtD
Pimecrolimus—Pruritus—Pentoxifylline—systemic scleroderma	0.000902	0.00138	CcSEcCtD
Pimecrolimus—Back pain—Mycophenolic acid—systemic scleroderma	0.0009	0.00138	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000899	0.00138	CcSEcCtD
Pimecrolimus—Flushing—Lisinopril—systemic scleroderma	0.000894	0.00137	CcSEcCtD
Pimecrolimus—Angioedema—Leflunomide—systemic scleroderma	0.000891	0.00136	CcSEcCtD
Pimecrolimus—Epistaxis—Mycophenolate mofetil—systemic scleroderma	0.000887	0.00136	CcSEcCtD
Pimecrolimus—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.000882	0.00135	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00088	0.00135	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—IL1B—systemic scleroderma	0.00088	0.00344	CbGpPWpGaD
Pimecrolimus—Arthralgia—Azathioprine—systemic scleroderma	0.00088	0.00135	CcSEcCtD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000876	0.00343	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000873	0.00134	CcSEcCtD
Pimecrolimus—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000872	0.00133	CcSEcCtD
Pimecrolimus—Abdominal pain—Mometasone—systemic scleroderma	0.00087	0.00133	CcSEcCtD
Pimecrolimus—Body temperature increased—Mometasone—systemic scleroderma	0.00087	0.00133	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000868	0.00133	CcSEcCtD
Pimecrolimus—Paraesthesia—Captopril—systemic scleroderma	0.000867	0.00133	CcSEcCtD
Pimecrolimus—Dyspnoea—Captopril—systemic scleroderma	0.000861	0.00132	CcSEcCtD
Pimecrolimus—Cough—Leflunomide—systemic scleroderma	0.000851	0.0013	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000846	0.00331	CbGpPWpGaD
Pimecrolimus—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.000846	0.00129	CcSEcCtD
Pimecrolimus—Malnutrition—Lisinopril—systemic scleroderma	0.000838	0.00128	CcSEcCtD
Pimecrolimus—Erythema—Lisinopril—systemic scleroderma	0.000838	0.00128	CcSEcCtD
Pimecrolimus—Infection—Azathioprine—systemic scleroderma	0.000838	0.00128	CcSEcCtD
Pimecrolimus—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.000837	0.00128	CcSEcCtD
Pimecrolimus—Arthralgia—Leflunomide—systemic scleroderma	0.000831	0.00127	CcSEcCtD
Pimecrolimus—Constipation—Captopril—systemic scleroderma	0.000826	0.00126	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000825	0.00126	CcSEcCtD
Pimecrolimus—Skin disorder—Azathioprine—systemic scleroderma	0.000819	0.00125	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000815	0.00319	CbGpPWpGaD
Pimecrolimus—Cough—Mycophenolic acid—systemic scleroderma	0.000812	0.00124	CcSEcCtD
Pimecrolimus—Back pain—Lisinopril—systemic scleroderma	0.000811	0.00124	CcSEcCtD
Pimecrolimus—Vomiting—Pentoxifylline—systemic scleroderma	0.000811	0.00124	CcSEcCtD
Pimecrolimus—Rash—Pentoxifylline—systemic scleroderma	0.000804	0.00123	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—SMAD7—systemic scleroderma	0.000803	0.00314	CbGpPWpGaD
Pimecrolimus—Dermatitis—Pentoxifylline—systemic scleroderma	0.000803	0.00123	CcSEcCtD
Pimecrolimus—Headache—Pentoxifylline—systemic scleroderma	0.000799	0.00122	CcSEcCtD
Pimecrolimus—Face oedema—Prednisone—systemic scleroderma	0.000798	0.00122	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000796	0.00122	CcSEcCtD
Pimecrolimus—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000792	0.00121	CcSEcCtD
Pimecrolimus—Infection—Leflunomide—systemic scleroderma	0.000791	0.00121	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Captopril—systemic scleroderma	0.00079	0.00121	CcSEcCtD
Pimecrolimus—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000789	0.00121	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000787	0.0012	CcSEcCtD
Pimecrolimus—Nervous system disorder—Leflunomide—systemic scleroderma	0.000781	0.00119	CcSEcCtD
Pimecrolimus—Pruritus—Mometasone—systemic scleroderma	0.000778	0.00119	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000778	0.00304	CbGpPWpGaD
Pimecrolimus—Skin disorder—Leflunomide—systemic scleroderma	0.000773	0.00118	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000768	0.00118	CcSEcCtD
Pimecrolimus—Angioedema—Lisinopril—systemic scleroderma	0.000766	0.00117	CcSEcCtD
Pimecrolimus—Abdominal pain—Captopril—systemic scleroderma	0.000764	0.00117	CcSEcCtD
Pimecrolimus—Body temperature increased—Captopril—systemic scleroderma	0.000764	0.00117	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00076	0.00116	CcSEcCtD
Pimecrolimus—Oedema—Mycophenolic acid—systemic scleroderma	0.00076	0.00116	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000758	0.00296	CbGpPWpGaD
Pimecrolimus—Nausea—Pentoxifylline—systemic scleroderma	0.000757	0.00116	CcSEcCtD
Pimecrolimus—Infection—Mycophenolic acid—systemic scleroderma	0.000755	0.00115	CcSEcCtD
Pimecrolimus—Diarrhoea—Mometasone—systemic scleroderma	0.000753	0.00115	CcSEcCtD
Pimecrolimus—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000745	0.00114	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000739	0.00289	CbGpPWpGaD
Pimecrolimus—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000738	0.00113	CcSEcCtD
Pimecrolimus—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000734	0.00112	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—NOS3—systemic scleroderma	0.000734	0.00287	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFBI—systemic scleroderma	0.000734	0.00287	CbGpPWpGaD
Pimecrolimus—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000732	0.00112	CcSEcCtD
Pimecrolimus—Cough—Lisinopril—systemic scleroderma	0.000732	0.00112	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000728	0.00111	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000725	0.00111	CcSEcCtD
Pimecrolimus—Paraesthesia—Leflunomide—systemic scleroderma	0.000715	0.00109	CcSEcCtD
Pimecrolimus—Arthralgia—Lisinopril—systemic scleroderma	0.000714	0.00109	CcSEcCtD
Pimecrolimus—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00071	0.00109	CcSEcCtD
Pimecrolimus—Dyspnoea—Leflunomide—systemic scleroderma	0.00071	0.00109	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000709	0.00108	CcSEcCtD
Pimecrolimus—Vomiting—Mometasone—systemic scleroderma	0.000699	0.00107	CcSEcCtD
Pimecrolimus—Rash—Mometasone—systemic scleroderma	0.000694	0.00106	CcSEcCtD
Pimecrolimus—Dermatitis—Mometasone—systemic scleroderma	0.000693	0.00106	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000692	0.00106	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000689	0.00105	CcSEcCtD
Pimecrolimus—Headache—Mometasone—systemic scleroderma	0.000689	0.00105	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000687	0.00105	CcSEcCtD
Pimecrolimus—Oedema—Lisinopril—systemic scleroderma	0.000684	0.00105	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000684	0.00105	CcSEcCtD
Pimecrolimus—Pruritus—Captopril—systemic scleroderma	0.000683	0.00105	CcSEcCtD
Pimecrolimus—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000682	0.00104	CcSEcCtD
Pimecrolimus—Pain—Leflunomide—systemic scleroderma	0.000681	0.00104	CcSEcCtD
Pimecrolimus—Constipation—Leflunomide—systemic scleroderma	0.000681	0.00104	CcSEcCtD
Pimecrolimus—Infection—Lisinopril—systemic scleroderma	0.00068	0.00104	CcSEcCtD
Pimecrolimus—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000677	0.00104	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000672	0.00263	CbGpPWpGaD
Pimecrolimus—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000671	0.00103	CcSEcCtD
Pimecrolimus—Abdominal pain—Azathioprine—systemic scleroderma	0.000667	0.00102	CcSEcCtD
Pimecrolimus—Body temperature increased—Azathioprine—systemic scleroderma	0.000667	0.00102	CcSEcCtD
Pimecrolimus—Skin disorder—Lisinopril—systemic scleroderma	0.000665	0.00102	CcSEcCtD
Pimecrolimus—Diarrhoea—Captopril—systemic scleroderma	0.000661	0.00101	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000656	0.001	CcSEcCtD
Pimecrolimus—Nausea—Mometasone—systemic scleroderma	0.000653	0.001	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000651	0.000996	CcSEcCtD
Pimecrolimus—Constipation—Mycophenolic acid—systemic scleroderma	0.00065	0.000994	CcSEcCtD
Pimecrolimus—Pain—Mycophenolic acid—systemic scleroderma	0.00065	0.000994	CcSEcCtD
Pimecrolimus—Cough—Mycophenolate mofetil—systemic scleroderma	0.000641	0.000981	CcSEcCtD
Pimecrolimus—Urticaria—Leflunomide—systemic scleroderma	0.000633	0.000968	CcSEcCtD
Pimecrolimus—Body temperature increased—Leflunomide—systemic scleroderma	0.000629	0.000963	CcSEcCtD
Pimecrolimus—Abdominal pain—Leflunomide—systemic scleroderma	0.000629	0.000963	CcSEcCtD
Pimecrolimus—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000625	0.000957	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000624	0.00244	CbGpPWpGaD
Pimecrolimus—Breast disorder—Methotrexate—systemic scleroderma	0.000624	0.000955	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000623	0.000954	CcSEcCtD
Pimecrolimus—Hypersensitivity—Azathioprine—systemic scleroderma	0.000621	0.00095	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000621	0.00095	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000621	0.00095	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—IL1A—systemic scleroderma	0.000616	0.00241	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Lisinopril—systemic scleroderma	0.000614	0.00094	CcSEcCtD
Pimecrolimus—Vomiting—Captopril—systemic scleroderma	0.000614	0.00094	CcSEcCtD
Pimecrolimus—Dyspnoea—Lisinopril—systemic scleroderma	0.00061	0.000933	CcSEcCtD
Pimecrolimus—Rash—Captopril—systemic scleroderma	0.000609	0.000932	CcSEcCtD
Pimecrolimus—Dermatitis—Captopril—systemic scleroderma	0.000609	0.000931	CcSEcCtD
Pimecrolimus—Headache—Captopril—systemic scleroderma	0.000605	0.000926	CcSEcCtD
Pimecrolimus—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.0006	0.000919	CcSEcCtD
Pimecrolimus—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.0006	0.000919	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000599	0.000917	CcSEcCtD
Pimecrolimus—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000599	0.000917	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—systemic scleroderma	0.000597	0.000914	CcSEcCtD
Pimecrolimus—Infection—Mycophenolate mofetil—systemic scleroderma	0.000596	0.000911	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000591	0.000904	CcSEcCtD
Pimecrolimus—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000588	0.000899	CcSEcCtD
Pimecrolimus—Hypersensitivity—Leflunomide—systemic scleroderma	0.000587	0.000897	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—HSPG2—systemic scleroderma	0.000586	0.00229	CbGpPWpGaD
Pimecrolimus—Pain—Lisinopril—systemic scleroderma	0.000585	0.000895	CcSEcCtD
Pimecrolimus—Constipation—Lisinopril—systemic scleroderma	0.000585	0.000895	CcSEcCtD
Pimecrolimus—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000582	0.000891	CcSEcCtD
Pimecrolimus—Diarrhoea—Azathioprine—systemic scleroderma	0.000577	0.000883	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000575	0.00225	CbGpPWpGaD
Pimecrolimus—Nausea—Captopril—systemic scleroderma	0.000574	0.000878	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CSK—systemic scleroderma	0.000568	0.00222	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CSK—systemic scleroderma	0.000566	0.00221	CbGpPWpGaD
Pimecrolimus—Pruritus—Leflunomide—systemic scleroderma	0.000563	0.000862	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—SMAD7—systemic scleroderma	0.000562	0.0022	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000559	0.000856	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000558	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD247—systemic scleroderma	0.000556	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ITGAM—systemic scleroderma	0.000556	0.00218	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000555	0.000849	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000546	0.000836	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000545	0.000834	CcSEcCtD
Pimecrolimus—Diarrhoea—Leflunomide—systemic scleroderma	0.000545	0.000833	CcSEcCtD
Pimecrolimus—Urticaria—Lisinopril—systemic scleroderma	0.000544	0.000831	CcSEcCtD
Pimecrolimus—Body temperature increased—Lisinopril—systemic scleroderma	0.000541	0.000827	CcSEcCtD
Pimecrolimus—Abdominal pain—Lisinopril—systemic scleroderma	0.000541	0.000827	CcSEcCtD
Pimecrolimus—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000823	CcSEcCtD
Pimecrolimus—Pruritus—Mycophenolic acid—systemic scleroderma	0.000537	0.000822	CcSEcCtD
Pimecrolimus—Vomiting—Azathioprine—systemic scleroderma	0.000536	0.00082	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—systemic scleroderma	0.000536	0.000819	CcSEcCtD
Pimecrolimus—Eye disorder—Prednisone—systemic scleroderma	0.000534	0.000818	CcSEcCtD
Pimecrolimus—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000534	0.000818	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD247—systemic scleroderma	0.000534	0.00209	CbGpPWpGaD
Pimecrolimus—Infestation NOS—Methotrexate—systemic scleroderma	0.000532	0.000815	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—systemic scleroderma	0.000532	0.000815	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—CD247—systemic scleroderma	0.000532	0.00208	CbGpPWpGaD
Pimecrolimus—Rash—Azathioprine—systemic scleroderma	0.000532	0.000813	CcSEcCtD
Pimecrolimus—Dermatitis—Azathioprine—systemic scleroderma	0.000531	0.000813	CcSEcCtD
Pimecrolimus—Flushing—Prednisone—systemic scleroderma	0.000531	0.000812	CcSEcCtD
Pimecrolimus—Headache—Azathioprine—systemic scleroderma	0.000528	0.000808	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000522	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TNFAIP3—systemic scleroderma	0.000521	0.00204	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00052	0.000795	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—systemic scleroderma	0.000518	0.000792	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000518	0.000792	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—systemic scleroderma	0.000517	0.00079	CcSEcCtD
Pimecrolimus—Pain—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000784	CcSEcCtD
Pimecrolimus—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000784	CcSEcCtD
Pimecrolimus—Vomiting—Leflunomide—systemic scleroderma	0.000506	0.000774	CcSEcCtD
Pimecrolimus—Hypersensitivity—Lisinopril—systemic scleroderma	0.000504	0.000771	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—systemic scleroderma	0.000502	0.000768	CcSEcCtD
Pimecrolimus—Rash—Leflunomide—systemic scleroderma	0.000502	0.000768	CcSEcCtD
Pimecrolimus—Dermatitis—Leflunomide—systemic scleroderma	0.000502	0.000767	CcSEcCtD
Pimecrolimus—Nausea—Azathioprine—systemic scleroderma	0.000501	0.000766	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000501	0.00196	CbGpPWpGaD
Pimecrolimus—Headache—Leflunomide—systemic scleroderma	0.000499	0.000763	CcSEcCtD
Pimecrolimus—Malnutrition—Prednisone—systemic scleroderma	0.000498	0.000762	CcSEcCtD
Pimecrolimus—Erythema—Prednisone—systemic scleroderma	0.000498	0.000762	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—BLK—systemic scleroderma	0.000494	0.00193	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00049	0.00075	CcSEcCtD
Pimecrolimus—Pruritus—Lisinopril—systemic scleroderma	0.000484	0.000741	CcSEcCtD
Pimecrolimus—Vomiting—Mycophenolic acid—systemic scleroderma	0.000483	0.000739	CcSEcCtD
Pimecrolimus—Rash—Mycophenolic acid—systemic scleroderma	0.000479	0.000733	CcSEcCtD
Pimecrolimus—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000478	0.000732	CcSEcCtD
Pimecrolimus—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000476	0.000729	CcSEcCtD
Pimecrolimus—Headache—Mycophenolic acid—systemic scleroderma	0.000476	0.000728	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—systemic scleroderma	0.000474	0.000726	CcSEcCtD
Pimecrolimus—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000474	0.000725	CcSEcCtD
Pimecrolimus—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000474	0.000725	CcSEcCtD
Pimecrolimus—Nausea—Leflunomide—systemic scleroderma	0.000473	0.000724	CcSEcCtD
Pimecrolimus—Diarrhoea—Lisinopril—systemic scleroderma	0.000468	0.000716	CcSEcCtD
Pimecrolimus—Angioedema—Prednisone—systemic scleroderma	0.000455	0.000696	CcSEcCtD
Pimecrolimus—MTOR—Disease—SMAD7—systemic scleroderma	0.000452	0.00177	CbGpPWpGaD
Pimecrolimus—Nausea—Mycophenolic acid—systemic scleroderma	0.000451	0.00069	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—systemic scleroderma	0.000447	0.000683	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000442	0.000676	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—RHOB—systemic scleroderma	0.000435	0.0017	CbGpPWpGaD
Pimecrolimus—Vomiting—Lisinopril—systemic scleroderma	0.000435	0.000665	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—systemic scleroderma	0.000432	0.00066	CcSEcCtD
Pimecrolimus—Rash—Lisinopril—systemic scleroderma	0.000431	0.00066	CcSEcCtD
Pimecrolimus—Dermatitis—Lisinopril—systemic scleroderma	0.000431	0.000659	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000431	0.000659	CcSEcCtD
Pimecrolimus—Headache—Lisinopril—systemic scleroderma	0.000429	0.000656	CcSEcCtD
Pimecrolimus—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000424	0.000649	CcSEcCtD
Pimecrolimus—Arthralgia—Prednisone—systemic scleroderma	0.000424	0.000648	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000421	0.000644	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—systemic scleroderma	0.000416	0.000637	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—systemic scleroderma	0.000416	0.000637	CcSEcCtD
Pimecrolimus—MTOR—Disease—TGFBI—systemic scleroderma	0.000413	0.00162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HSPG2—systemic scleroderma	0.00041	0.0016	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00041	0.000627	CcSEcCtD
Pimecrolimus—Nausea—Lisinopril—systemic scleroderma	0.000406	0.000622	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—systemic scleroderma	0.000406	0.000622	CcSEcCtD
Pimecrolimus—Oedema—Prednisone—systemic scleroderma	0.000406	0.000622	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CTLA4—systemic scleroderma	0.000405	0.00158	CbGpPWpGaD
Pimecrolimus—Infection—Prednisone—systemic scleroderma	0.000404	0.000618	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—systemic scleroderma	0.000402	0.000616	CcSEcCtD
Pimecrolimus—Nervous system disorder—Prednisone—systemic scleroderma	0.000398	0.00061	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CSK—systemic scleroderma	0.000396	0.00155	CbGpPWpGaD
Pimecrolimus—Skin disorder—Prednisone—systemic scleroderma	0.000395	0.000604	CcSEcCtD
Pimecrolimus—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000381	0.000583	CcSEcCtD
Pimecrolimus—Rash—Mycophenolate mofetil—systemic scleroderma	0.000378	0.000578	CcSEcCtD
Pimecrolimus—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000378	0.000578	CcSEcCtD
Pimecrolimus—Headache—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000574	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00037	0.000566	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisone—systemic scleroderma	0.000365	0.000558	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—systemic scleroderma	0.000363	0.000555	CcSEcCtD
Pimecrolimus—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000356	0.000545	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—systemic scleroderma	0.000354	0.000542	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000352	0.000538	CcSEcCtD
Pimecrolimus—Constipation—Prednisone—systemic scleroderma	0.000347	0.000532	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CSK—systemic scleroderma	0.000345	0.00135	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00034	0.00052	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IRF5—systemic scleroderma	0.000339	0.00133	CbGpPWpGaD
Pimecrolimus—Infection—Methotrexate—systemic scleroderma	0.000337	0.000516	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000333	0.0013	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Methotrexate—systemic scleroderma	0.000333	0.000509	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000332	0.000508	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—systemic scleroderma	0.00033	0.000505	CcSEcCtD
Pimecrolimus—MTOR—Disease—HSPG2—systemic scleroderma	0.000329	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRF8—systemic scleroderma	0.000324	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ITGAM—systemic scleroderma	0.000324	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD247—systemic scleroderma	0.000324	0.00127	CbGpPWpGaD
Pimecrolimus—Urticaria—Prednisone—systemic scleroderma	0.000323	0.000494	CcSEcCtD
Pimecrolimus—Body temperature increased—Prednisone—systemic scleroderma	0.000321	0.000491	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—systemic scleroderma	0.000321	0.000491	CcSEcCtD
Pimecrolimus—MTOR—Disease—CSK—systemic scleroderma	0.000318	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD7—systemic scleroderma	0.000316	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40LG—systemic scleroderma	0.000315	0.00123	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000309	0.000473	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—systemic scleroderma	0.000305	0.000466	CcSEcCtD
Pimecrolimus—MTOR—Immune System—TNFAIP3—systemic scleroderma	0.000303	0.00119	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Methotrexate—systemic scleroderma	0.000303	0.000463	CcSEcCtD
Pimecrolimus—MTOR—Immune System—BLK—systemic scleroderma	0.0003	0.00117	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Prednisone—systemic scleroderma	0.000299	0.000458	CcSEcCtD
Pimecrolimus—MTOR—Disease—CD247—systemic scleroderma	0.000299	0.00117	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000293	0.000449	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—systemic scleroderma	0.00029	0.000444	CcSEcCtD
Pimecrolimus—Pruritus—Prednisone—systemic scleroderma	0.000287	0.00044	CcSEcCtD
Pimecrolimus—Diarrhoea—Prednisone—systemic scleroderma	0.000278	0.000425	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000278	0.000425	CcSEcCtD
Pimecrolimus—Urticaria—Methotrexate—systemic scleroderma	0.00027	0.000413	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—systemic scleroderma	0.000268	0.000411	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—systemic scleroderma	0.000268	0.000411	CcSEcCtD
Pimecrolimus—Vomiting—Prednisone—systemic scleroderma	0.000258	0.000395	CcSEcCtD
Pimecrolimus—Rash—Prednisone—systemic scleroderma	0.000256	0.000392	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—systemic scleroderma	0.000256	0.000392	CcSEcCtD
Pimecrolimus—Headache—Prednisone—systemic scleroderma	0.000255	0.000389	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—systemic scleroderma	0.00025	0.000383	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CTLA4—systemic scleroderma	0.000246	0.000961	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RHOB—systemic scleroderma	0.000245	0.000957	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisone—systemic scleroderma	0.000241	0.000369	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—systemic scleroderma	0.00024	0.000368	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—systemic scleroderma	0.000232	0.000355	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—HSPG2—systemic scleroderma	0.000231	0.000903	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CSK—systemic scleroderma	0.000223	0.000872	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EDN1—systemic scleroderma	0.000222	0.000869	CbGpPWpGaD
Pimecrolimus—Vomiting—Methotrexate—systemic scleroderma	0.000216	0.00033	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—systemic scleroderma	0.000214	0.000328	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—systemic scleroderma	0.000214	0.000327	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—systemic scleroderma	0.000213	0.000325	CcSEcCtD
Pimecrolimus—MTOR—Immune System—HLA-DQB1—systemic scleroderma	0.000202	0.000791	CbGpPWpGaD
Pimecrolimus—Nausea—Methotrexate—systemic scleroderma	0.000202	0.000309	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—NOS3—systemic scleroderma	0.000193	0.000756	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1A—systemic scleroderma	0.000192	0.000751	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—systemic scleroderma	0.000191	0.000747	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—systemic scleroderma	0.000152	0.000594	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—systemic scleroderma	0.000135	0.000529	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—systemic scleroderma	0.000128	0.0005	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDN1—systemic scleroderma	0.000125	0.000489	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—systemic scleroderma	0.000109	0.000425	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—systemic scleroderma	0.000109	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—systemic scleroderma	0.0001	0.000392	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—systemic scleroderma	8.95e-05	0.00035	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—systemic scleroderma	8.54e-05	0.000334	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—systemic scleroderma	7.61e-05	0.000298	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSPG2—systemic scleroderma	7.32e-05	0.000286	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—systemic scleroderma	7.19e-05	0.000281	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—systemic scleroderma	6.11e-05	0.000239	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CTGF—systemic scleroderma	5.55e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—systemic scleroderma	5.03e-05	0.000197	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.41e-05	9.44e-05	CbGpPWpGaD
